既往间质性肺病对一线免疫检查点抑制剂治疗NSCLC肺炎风险与生存的影响
这项多中心回顾性队列纳入1340例接受一线免疫检查点抑制剂(ICI)治疗的晚期或复发非小细胞肺癌(NSCLC)患者,158例(11.8%)有既往间质性肺病(ILD)。既往ILD与任何级别肺炎、≥3级肺炎风险升高及总生存(OS)较差独立相关;在ILD患者中,可能普通型间质性肺炎(UIP)/UIP型与更高的肺炎风险和更短的OS相关。
要点
- 既往ILD患者任何级别肺炎风险升高(校正sHR 2.64),≥3级肺炎风险亦升高(校正sHR 2.18)。
- 既往ILD与更差OS独立相关(校正HR 1.36)。
- ILD患者中可能UIP/UIP型肺炎风险更高且OS更短,治疗前HRCT评估有助于个体化风险获益判断。
核心结论
- 在接受一线ICI为基础治疗的NSCLC患者中,既往ILD与更高的肺炎风险和更短的生存相关。
- 在ILD患者中,可能UIP/UIP型可能识别出预后特别差的一个亚组。
- 治疗前HRCT评估可能有助于个体化风险获益评估。
研究设计与样本
- 多中心回顾性队列研究,纳入2017至2022年在15家日本机构接受一线ICI为基础治疗的晚期或复发NSCLC患者1340例。
- 既往ILD及高分辨率计算机断层扫描(HRCT)模式经中心审核。
- 采用Fine-Gray和Cox模型分析肺炎和总生存(OS)。
主要发现
- 1340例患者中158例(11.8%)有既往ILD。
- 既往ILD与任何级别肺炎风险升高独立相关(校正sHR 2.64;95%CI 1.91-3.65)。
- 既往ILD与≥3级肺炎风险升高独立相关(校正sHR 2.18;95%CI 1.37-3.47)。
- 既往ILD与更差OS独立相关(校正HR 1.36;95%CI 1.12-1.66)。
- 肺炎发生后死亡风险增加,尤其是≥3级肺炎(校正HR 2.25;95%CI 1.71-2.96),且ILD患者肺炎临床过程更差。
临床怎么用
- 对拟接受一线ICI为基础治疗的NSCLC患者,治疗前应评估是否存在既往ILD。
- 对存在既往ILD者,可结合治疗前HRCT模式(尤其可能UIP/UIP型)进行个体化风险获益评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence remains limited regarding first-line immune checkpoint inhibitor (ICI)-based therapy in patients with non-small cell lung cancer (NSCLC) and preexisting interstitial lung disease (ILD). We evaluated pneumonitis risk and survival based on preexisting ILD status and explored risk stratification in patients with ILD. METHODS: This multicenter retrospective cohort study included 1340 patients with advanced or recurrent NSCLC receiving first-line ICI-based therapy at 15 Japanese institutions between 2017 and 2022. Preexisting ILD and high-resolution computed tomography (HRCT) patterns were centrally reviewed. Pneumonitis and overall survival (OS) were analyzed using Fine-Gray and Cox models. RESULTS: Among 1340 patients, 158 (11.8%) had preexisting ILD. Preexisting ILD was independently associated with higher risks of any-grade pneumonitis (adjusted subdistribution hazard ratio [sHR], 2.64; 95% confidence interval [CI], 1.91-3.65) and grade ≥ 3 pneumonitis (adjusted sHR, 2.18; 95% CI, 1.37-3.47) and with worse OS (adjusted HR, 1.36; 95% CI, 1.12-1.66). Pneumonitis onset was followed by an increased risk of death, particularly for grade ≥ 3 pneumonitis (adjusted HR, 2.25; 95% CI, 1.71-2.96), and its clinical course was poorer in patients with ILD. In patients with ILD, probable usual interstitial pneumonia (UIP)/UIP pattern was associated with higher pneumonitis risk (adjusted sHR, 2.18; 95% CI, 1.27-3.74) and shorter OS (adjusted HR, 2.88; 95% CI, 1.80-4.61). CONCLUSIONS: Among patients receiving first-line ICI-based therapy, preexisting ILD was associated with a higher risk of pneumonitis and shorter survival. In patients with ILD, probable UIP/UIP pattern may identify a subgroup with particularly poor outcomes. Pretreatment HRCT evaluation may therefore be useful for individualized risk-benefit assessment.
引用
- Matsumoto K, Yamamoto Y, Shiroyama T, et al. Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer. Eur J Cancer. 2026. PMID: 42349343. doi:10.1016/j.ejca.2026.116902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。